树突细胞疫苗:从传统方法转向新一代疫苗
Kyu-Won Lee1, Judy Wai Ping Yam1,2, Xiaowen Mao3
1Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Cells
|September 8, 2023
概括
新的树突细胞 (DC) 疫苗有望克服癌症免疫治疗的局限性,比目前的免疫检查点阻塞 (ICB) 和采用细胞转移疗法 (ACT) 等治疗方法提供潜在的改进. 本综述探讨了用于增强癌症治疗的先进DC疫苗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 癌症免疫疗法,包括免疫检查点阻塞 (ICB) 和采用细胞转移疗法 (ACT),面临诸如感冒瘤和免疫抑制微环境等挑战.
- 基于树突细胞 (DC) 的疫苗为解决这些局限性和提高治疗疗效提供了一个有希望的替代方案.
- 虽然第一代DC疫苗 (Provenge) 取得了成功,但为了克服现有挑战,需要进一步的进展.
研究的目的:
- 在癌症免疫治疗中审查经典DC疫苗的局限性.
- 评估新的DC疫苗策略,包括基于生物材料,免疫细胞死亡诱导,mRNA脉冲和基于小细胞外囊 (sEV) 的方法.
- 突出创新的DC疫苗在推进癌症治疗中的潜力.
主要方法:
- 对当前和新兴的DC疫苗策略的文献综述.
- 分析与现有的癌症免疫疗法 (ICB,ACT) 相关的局限性.
- 对下一代DC疫苗的评估:基于生物材料,免疫细胞死亡诱导,mRNA脉冲,基于DCsEV和基于瘤sEV.
主要成果:
- 经典的DC疫苗在治疗感冒瘤和克服免疫抑制瘤微环境方面存在局限性.
- 新一代DC疫苗显示出增强抗瘤免疫力和减轻免疫相关副作用的潜力.
- 像mRNA脉冲和sEV基DC疫苗这样的创新策略显示出改善治疗结果的希望.
结论:
- 先进的DC疫苗策略对于克服当前癌症免疫治疗的局限性至关重要.
- 新型DC疫苗,包括利用生物材料,mRNA和sEVs的疫苗,代表了癌症治疗的重大突破.
- 进一步的临床前和临床研究对于验证这些创新的DC疫苗的疗效至关重要.
更多相关视频
相关概念视频
01:51Vaccinations
44.7K
Overview
44.7K
01:30Cancer Vaccines
399
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
399
01:24B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
01:22T Cell Activation and Clonal Selection
801
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
801